Watchman LAA Closure Device Enrolling by Invitation Phase 4 Trials for Dabigatran etexilate (DB06695)

IndicationStatusPhase
DBCOND0111559 (Watchman LAA Closure Device)Enrolling by Invitation4
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03539055Efficacy of Short Term Dabigatran Etexilate Followed by Aspirin Monotherapy After LAA (Left Atrial Appendage) Device Closure (the DEA-LAA Study).Prevention